Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $14.68 billion. The enterprise value is $21.29 billion.
Important Dates
The next estimated earnings date is Thursday, February 13, 2025, before market open.
| Earnings Date | Feb 13, 2025 |
| Ex-Dividend Date | Nov 15, 2024 |
Share Statistics
Royalty Pharma has 589.18 million shares outstanding. The number of shares has increased by 33.46% in one year.
| Current Share Class | 444.30M |
| Shares Outstanding | 589.18M |
| Shares Change (YoY) | +33.46% |
| Shares Change (QoQ) | -0.70% |
| Owned by Insiders (%) | 13.55% |
| Owned by Institutions (%) | 72.18% |
| Float | 383.92M |
Valuation Ratios
The trailing PE ratio is 9.76 and the forward PE ratio is 5.97.
| PE Ratio | 9.76 |
| Forward PE | 5.97 |
| PS Ratio | 4.93 |
| Forward PS | 5.37 |
| PB Ratio | 1.62 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | 5.25 |
| P/OCF Ratio | 5.25 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 18.59 |
| EV / Sales | 9.40 |
| EV / EBITDA | n/a |
| EV / EBIT | 13.79 |
| EV / FCF | 7.61 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.54 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.72 |
| Interest Coverage | 7.46 |
Financial Efficiency
Return on equity (ROE) is 17.28% and return on invested capital (ROIC) is 5.75%.
| Return on Equity (ROE) | 17.28% |
| Return on Assets (ROA) | 5.69% |
| Return on Capital (ROIC) | 5.75% |
| Revenue Per Employee | $25.46M |
| Profits Per Employee | $12.87M |
| Employee Count | 89 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.30% in the last 52 weeks. The beta is 0.46, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -10.30% |
| 50-Day Moving Average | 26.45 |
| 200-Day Moving Average | 27.59 |
| Relative Strength Index (RSI) | 38.92 |
| Average Volume (20 Days) | 3,330,648 |
Short Selling Information
The latest short interest is 15.70 million, so 2.67% of the outstanding shares have been sold short.
| Short Interest | 15.70M |
| Short Previous Month | 14.67M |
| Short % of Shares Out | 2.67% |
| Short % of Float | 4.09% |
| Short Ratio (days to cover) | 4.96 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.27 billion and earned $1.15 billion in profits. Earnings per share was $2.55.
| Revenue | 2.27B |
| Gross Profit | 1.77B |
| Operating Income | 1.54B |
| Pretax Income | 673.24M |
| Net Income | 1.15B |
| EBITDA | n/a |
| EBIT | 1.54B |
| Earnings Per Share (EPS) | $2.55 |
Full Income StatementBalance Sheet
The company has $998.55 million in cash and $7.61 billion in debt, giving a net cash position of -$6.61 billion or -$11.22 per share.
| Cash & Cash Equivalents | 998.55M |
| Total Debt | 7.61B |
| Net Cash | -6.61B |
| Net Cash Per Share | -$11.22 |
| Equity (Book Value) | 10.26B |
| Book Value Per Share | 15.40 |
| Working Capital | 626.44M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.80B |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.80B |
| FCF Per Share | $4.75 |
Full Cash Flow StatementMargins
Gross margin is 78.29%, with operating and profit margins of 68.13% and 50.53%.
| Gross Margin | 78.29% |
| Operating Margin | 68.13% |
| Pretax Margin | 75.64% |
| Profit Margin | 50.53% |
| EBITDA Margin | n/a |
| EBIT Margin | 68.13% |
| FCF Margin | 123.53% |
Dividends & Yields
This stock pays an annual dividend of $0.84, which amounts to a dividend yield of 3.37%.
| Dividend Per Share | $0.84 |
| Dividend Yield | 3.37% |
| Dividend Growth (YoY) | 5.00% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 32.89% |
| Buyback Yield | -33.46% |
| Shareholder Yield | -30.09% |
| Earnings Yield | 7.80% |
| FCF Yield | 19.06% |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $41.67, which is 67.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.67 |
| Price Target Difference | 67.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 4.06% |
| EPS Growth Forecast (5Y) | 19.27% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.63 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.63 |
| Piotroski F-Score | 5 |